Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy

Background: Homozygosity at HLA-I locus has been reported to be an unfavorable predictive biomarker of second-line or beyond immunotherapy in patients with different types of cancer. The linkage between HLA-I zygosity and survival in NSCLC patients treated with first-line immunotherapy with or witho...

Full description

Bibliographic Details
Main Authors: Dongyup Lee, Jonghanne Park, Horyun Choi, Gahyun Gim, Sukjoo Cho, Leeseul Kim, Youjin Oh, Cyra Y. Kang, Yeseul Kim, Dean Tan, Pedro Antonio Hermida de Viveiros, Young Kwang Chae
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Heliyon
Subjects:
Non-small cell lung cancer
Immunotherapy
Human leukocyte antigen
Heterozygosity
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844021020193

Internet

http://www.sciencedirect.com/science/article/pii/S2405844021020193

Similar Items